Physician profile
Scott W Sims
NPI 1356346852
$4,460.12
in general payments reported to CMS, 2019-2025
24 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $158 · 2021: $510 · 2022: $483 · 2023: $553 · 2024: $1,048 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Travel and Lodging: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.66 |
| Travel and Lodging | $302.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $725.20 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $714.29 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $550.82 | 2024-2025 | Ingevity+, Cds - Other |
| Amgen INC. | $444.43 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $397.89 | 2019-2025 | |
| Medtronic Vascular, INC. | $284.22 | 2019 | |
| Edwards Lifesciences Corporation | $251.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.63 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $175.33 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $106.97 | 2019-2024 | |
| Siemens Medical Solutions USA, INC. | $92.31 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $89.26 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $88.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $79.69 | 2019-2025 | Eliquis |
| Philips North America LLC | $56.71 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Dd1) Duo Hybrid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.88 | 2022 | |
| Livanova USA, INC. | $24.99 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $21.13 | 2023 | Arcalyst |
| Abiomed | $19.05 | 2023 | Impella |
| Terumo Medical Corporation | $18.40 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $18.40 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $15.15 | 2023 | Optimizer |
| Celonova Biosciences, INC. | $14.27 | 2020 | |
| Baxter Healthcare | $13.81 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.